Buscar
Mostrando ítems 1-10 de 12
Subcutaneous Tanezumab for Osteoarthritis: Is the Early Improvement in Pain and Function Meaningful and Sustained?
(Wiley, 2021-03-16)
[Abstract] Background: To evaluate if early improvements in pain and function with subcuta-neous tanezumab are meaningful and sustained over 24 weeks.
Methods: Patients with moderate- to- severe osteoarthritis (hip or ...
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
(BMJ, 2020-03-31)
[Abstract] Objective. Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in a study with 24-week treatment and 24-week safety follow-up.
Methods. This double-blind, ...
Relationship Between Motion, Using the GaitSmartTM System, and Radiographic Knee Osteoarthritis: An Explorative Analysis in the IMI-APPROACH Cohort
(Oxford, 2020-12-25)
[Abstract] Objectives: To assess underlying domains measured by GaitSmartTMparameters and whether these are additional to established OA markers including patient reported outcome measures (PROMs) and radiographic parameters, ...
Cohort profile: the Applied Public-Private Research enabling OsteoArthritis Clinical Headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemical markers
(BMJ, 2020-07-28)
[Abstract] Purpose The Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH) consortium intends to prospectively describe in detail, preselected patients with knee osteoarthritis (OA), using ...
Neuropathic Pain in the IMI-APPROACH Knee Osteoarthritis Cohort: Prevalence and Phenotyping
(BMJ, 2021-12-15)
[Abstract] Objectives: Osteoarthritis (OA) patients with a neuropathic pain (NP) component may represent a specific phenotype. This study compares joint damage, pain and functional disability between knee OA patients with ...
Baseline clinical characteristics of predicted structural and pain progressors in the IMI-APPROACH knee OA cohort
(BMJ, 2021-08-23)
[Abstract] Objectives: To describe the relations between baseline clinical characteristics of the Applied Public-Private Research enabling OsteoArthritis Clinical Headway (IMI-APPROACH) participants and their predicted ...
Core Outcome Measurement Instrument Selection for Physical Function in Hand Osteoarthritis Using the OMERACT Filter 2.1 Process
(Elsevier, 2021-12)
[Abstract] Objective: Physical function is one of the Outcome Measures in Rheumatology (OMERACT) core outcome domains for hand osteoarthritis studies. Our aim was to select appropriate instrument(s) to measure this domain, ...
GaitSmart Motion Analysis Compared to Commonly Used Function Outcome Measures in the IMI-APPROACH Knee Osteoarthritis Cohort
(PLoS ONE, 2022-03-23)
[Abstract] Background: There are multiple measures for assessment of physical function in knee osteoarthritis (OA), but each has its strengths and limitations. The GaitSmart® system, which uses inertial measurement units ...
Structural tissue damage and 24-month progression of semi-quantitative MRI biomarkers of knee osteoarthritis in the IMI-APPROACH cohort
(BioMed Central, 2022-11-17)
[Abstract] Background. The IMI-APPROACH cohort is an exploratory, 5-centre, 2-year prospective follow-up study of knee osteoarthritis (OA). Aim was to describe baseline multi-tissue semiquantitative MRI evaluation of index ...
Test–retest precision and longitudinal cartilage thickness loss in the IMI-APPROACH cohort
(Elsevier, 2022-11-03)
[Abstract] Objective. To investigate the test–retest precision and to report the longitudinal change in cartilage thickness, the percentage of knees with progression and the predictive value of the machine-learning-estimated ...